… Ruxolitinib is better than other available therapies in achieving hematocrit control and …
who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides …

… MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT)
in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was …

… vera who were resistant to or intolerant of hydroxyurea. We … ruxolitinib with best available
therapy in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea. …

… , thus insufficient data were available … ruxolitinib versus best available therapy in patients
with polycythaemia vera and splenomegaly who were resistant to or intolerant of hydroxyurea. …

… compared ruxolitinib with best available therapy in patients with splenomegaly who were
resistant to or intolerant to hydroxyurea. At 5 years, among 75 patients in the ruxolitinib group, …

… ruxolitinib = 93; best available therapy = 87) in which 74 patients were resistant/intolerant to
HU in the ruxolitinib … free survival was significantly improved with ruxolitinib (hazard ratio [HR]…

… vera who were resistant or intolerant of hydroxyurea. Exclusion … ruxolitinib, 10 mg BID versus
best available therapy, with … In this study, best available therapy used were hydroxyurea, …

… Ruxolitinib was compared to the best available therapy (BAT), which could include drugs
such as Hydroxycarbamide, … with PV who are resistant or intolerant to hydroxycarbamide. …

… trial comparing ruxolitinib versus best available therapy (BAT) … line therapy is not yet proven,
though hydroxycarbamide and … ruxolitinib in patients with PV who are resistant or intolerant …

… of ruxolitinib (Jakafi) as a treatment for adult patients with polycythemia vera that is intolerant
or resistant to hydroxycarbamide or hydroxyurea, … compared with best available therapy. …